Biopharma & Research Suppliers

The thesis

Pair commercial medicine developers with the research suppliers that support drug discovery and manufacturing, rather than concentrating on a single treatment class. Lilly's reimbursement debate puts durable demand, realized pricing and pipeline execution in focus while AI spending concerns pressure technology shares. The basket emphasizes established drug franchises, with research tools providing a complementary business model; pricing pressure and clinical setbacks remain key risks.